
John A. Ward
Examiner (ID: 10393)
| Most Active Art Unit | 2875 |
| Art Unit(s) | 2885, 2875 |
| Total Applications | 1293 |
| Issued Applications | 1015 |
| Pending Applications | 41 |
| Abandoned Applications | 239 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17183820
[patent_doc_number] => 20210330705
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-28
[patent_title] => TOLEROGENIC DENDRITIC CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME
[patent_app_type] => utility
[patent_app_number] => 17/237475
[patent_app_country] => US
[patent_app_date] => 2021-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11693
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17237475
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/237475 | TOLEROGENIC DENDRITIC CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME | Apr 21, 2021 | Abandoned |
Array
(
[id] => 18449535
[patent_doc_number] => 20230190811
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 17/996021
[patent_app_country] => US
[patent_app_date] => 2021-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 74874
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17996021
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/996021 | COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF CANCER | Apr 12, 2021 | Pending |
Array
(
[id] => 16945840
[patent_doc_number] => 20210204531
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-08
[patent_title] => COMMON LIGHT CHAIN MOUSE
[patent_app_type] => utility
[patent_app_number] => 17/209964
[patent_app_country] => US
[patent_app_date] => 2021-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19777
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17209964
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/209964 | COMMON LIGHT CHAIN MOUSE | Mar 22, 2021 | Abandoned |
Array
(
[id] => 17082111
[patent_doc_number] => 20210277117
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-09
[patent_title] => CONSTRUCTS TARGETING AFP PEPTIDE/MHC COMPLEXES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/203665
[patent_app_country] => US
[patent_app_date] => 2021-03-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 81604
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17203665
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/203665 | CONSTRUCTS TARGETING AFP PEPTIDE/MHC COMPLEXES AND USES THEREOF | Mar 15, 2021 | Abandoned |
Array
(
[id] => 17123509
[patent_doc_number] => 20210298277
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-30
[patent_title] => HUMAN ARTIFICIAL CHROMOSOME CONTAINING HUMAN ANTIBODY LAMBDA LIGHT CHAIN GENE AND NON-HUMAN ANIMAL CONTAINING THE HUMAN ARTIFICIAL CHROMOSOME CAPABLE OF GENETIC TRANSMISSION
[patent_app_type] => utility
[patent_app_number] => 17/196608
[patent_app_country] => US
[patent_app_date] => 2021-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14564
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17196608
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/196608 | HUMAN ARTIFICIAL CHROMOSOME CONTAINING HUMAN ANTIBODY LAMBDA LIGHT CHAIN GENE AND NON-HUMAN ANIMAL CONTAINING THE HUMAN ARTIFICIAL CHROMOSOME CAPABLE OF GENETIC TRANSMISSION | Mar 8, 2021 | Abandoned |
Array
(
[id] => 17586596
[patent_doc_number] => 11324838
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-10
[patent_title] => Gene editing to improve joint function
[patent_app_type] => utility
[patent_app_number] => 17/166343
[patent_app_country] => US
[patent_app_date] => 2021-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 16908
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 128
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17166343
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/166343 | Gene editing to improve joint function | Feb 2, 2021 | Issued |
Array
(
[id] => 19930347
[patent_doc_number] => 12303540
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-20
[patent_title] => RNA viruses for immunovirotherapy
[patent_app_type] => utility
[patent_app_number] => 17/166398
[patent_app_country] => US
[patent_app_date] => 2021-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 4398
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17166398
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/166398 | RNA viruses for immunovirotherapy | Feb 2, 2021 | Issued |
Array
(
[id] => 19403997
[patent_doc_number] => 20240287508
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-29
[patent_title] => MODIFIED FILAMINS AND THEIR USES
[patent_app_type] => utility
[patent_app_number] => 17/796968
[patent_app_country] => US
[patent_app_date] => 2021-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19259
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17796968
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/796968 | MODIFIED FILAMINS AND THEIR USES | Feb 1, 2021 | Pending |
Array
(
[id] => 16870155
[patent_doc_number] => 20210163622
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/163040
[patent_app_country] => US
[patent_app_date] => 2021-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45726
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17163040
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/163040 | IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF | Jan 28, 2021 | Abandoned |
Array
(
[id] => 19490064
[patent_doc_number] => 12108745
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-08
[patent_title] => Rat model of IgA nephropathy induced with a multimeric recombinant IgA fragment
[patent_app_type] => utility
[patent_app_number] => 17/155870
[patent_app_country] => US
[patent_app_date] => 2021-01-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 61
[patent_no_of_words] => 11549
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 140
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17155870
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/155870 | Rat model of IgA nephropathy induced with a multimeric recombinant IgA fragment | Jan 21, 2021 | Issued |
Array
(
[id] => 17290930
[patent_doc_number] => 20210386769
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => MOUSE MODEL AND TREATMENT OF HEREDITARY INCLUSION BODY MYOPATHY
[patent_app_type] => utility
[patent_app_number] => 17/152471
[patent_app_country] => US
[patent_app_date] => 2021-01-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7082
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17152471
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/152471 | MOUSE MODEL AND TREATMENT OF HEREDITARY INCLUSION BODY MYOPATHY | Jan 18, 2021 | Abandoned |
Array
(
[id] => 18348001
[patent_doc_number] => 20230136112
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => METHODS FOR STRATIFYING DIABETES PATIENTS
[patent_app_type] => utility
[patent_app_number] => 17/780141
[patent_app_country] => US
[patent_app_date] => 2020-11-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17641
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17780141
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/780141 | METHODS FOR STRATIFYING DIABETES PATIENTS | Nov 26, 2020 | Pending |
Array
(
[id] => 18075921
[patent_doc_number] => 20220401533
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => TREATMENT AND PROTECTION AGAINST ASPERGILLUS INFECTION AND ASPERGILLOSIS DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/776938
[patent_app_country] => US
[patent_app_date] => 2020-11-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22564
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17776938
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/776938 | TREATMENT AND PROTECTION AGAINST ASPERGILLUS INFECTION AND ASPERGILLOSIS DISEASE | Nov 11, 2020 | Abandoned |
Array
(
[id] => 16685904
[patent_doc_number] => 20210068379
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => HUMANIZED TRANSGENIC ANIMAL
[patent_app_type] => utility
[patent_app_number] => 17/089479
[patent_app_country] => US
[patent_app_date] => 2020-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16658
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17089479
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/089479 | Humanized transgenic animal | Nov 3, 2020 | Issued |
Array
(
[id] => 19194778
[patent_doc_number] => 11991994
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-05-28
[patent_title] => Method for producing recombinant proteins in insects
[patent_app_type] => utility
[patent_app_number] => 17/086226
[patent_app_country] => US
[patent_app_date] => 2020-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 9504
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 227
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17086226
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/086226 | Method for producing recombinant proteins in insects | Oct 29, 2020 | Issued |
Array
(
[id] => 18037554
[patent_doc_number] => 20220381770
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => ARTIFICIAL ANTIGEN PRESENTING MOLECULES AND THEIR USES
[patent_app_type] => utility
[patent_app_number] => 17/770877
[patent_app_country] => US
[patent_app_date] => 2020-10-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17646
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 99
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17770877
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/770877 | ARTIFICIAL ANTIGEN PRESENTING MOLECULES AND THEIR USES | Oct 22, 2020 | Pending |
Array
(
[id] => 18034730
[patent_doc_number] => 20220378945
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => GENE THERAPY TARGETING COCHLEAR CELLS
[patent_app_type] => utility
[patent_app_number] => 17/769952
[patent_app_country] => US
[patent_app_date] => 2020-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10317
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17769952
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/769952 | GENE THERAPY TARGETING COCHLEAR CELLS | Oct 18, 2020 | Pending |
Array
(
[id] => 19300059
[patent_doc_number] => 20240228628
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2024-07-11
[patent_title] => ANTIBODIES TARGETING FLT3 AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/769257
[patent_app_country] => US
[patent_app_date] => 2020-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31430
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -49
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17769257
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/769257 | ANTIBODIES TARGETING FLT3 AND USE THEREOF | Oct 13, 2020 | Abandoned |
Array
(
[id] => 19300059
[patent_doc_number] => 20240228628
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2024-07-11
[patent_title] => ANTIBODIES TARGETING FLT3 AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/769257
[patent_app_country] => US
[patent_app_date] => 2020-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31430
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -49
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17769257
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/769257 | ANTIBODIES TARGETING FLT3 AND USE THEREOF | Oct 12, 2020 | Abandoned |
Array
(
[id] => 19049352
[patent_doc_number] => 20240091321
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-21
[patent_title] => VARIANT IGF2 CONSTRUCTS
[patent_app_type] => utility
[patent_app_number] => 17/767803
[patent_app_country] => US
[patent_app_date] => 2020-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25688
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17767803
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/767803 | VARIANT IGF2 CONSTRUCTS | Oct 11, 2020 | Pending |